Otrivine Congestion Relief 0.1% Nasal Spray

(Xylometazoline hydrochloride)

PL 00030/0461

UKPAR

TABLE OF CONTENTS

Lay Summary .......................................................... Page 2
Scientific Discussion ................................................. Page 4
Steps Taken for Assessment .................................. Page 11
Summary of Product Characteristics ............... Page 12
Patient Information Leaflet ....................................... Page 13
Labelling ................................................................. Page 14
OTRIVINE CONGESTION RELIEF 0.1% NASAL SPRAY

PL 00030/0461

LAY SUMMARY

This is a summary of the public assessment report (PAR) for Otrivine Congestion Relief 0.1% Nasal Spray. It explains how Otrivine Congestion Relief 0.1% Nasal Spray was assessed and its authorisation recommended as well as its conditions of use. It is not intended to provide practical advice on how to use Otrivine Congestion Relief 0.1% Nasal Spray.

For practical information about using Otrivine Congestion Relief 0.1% Nasal Spray, patients should read the package leaflet or contact their doctor or pharmacist.

What is Otrivine Congestion Relief 0.1% Nasal Spray and what is it used for?
Otrivine Congestion Relief 0.1% Nasal Spray contains the active ingredient xylometazoline hydrochloride. It is applied in the nose to give relief from nasal congestion (blocked nose, including colds), perennial and allergic rhinitis (recurring inflammation of the nasal mucous membranes, including hay fever) and sinusitis.

How does Otrivine Congestion Relief 0.1% Nasal Spray work?
Xylometazoline hydrochloride helps to open up and clear the nasal passages by reducing excessive nasal secretions and returning the swollen blood vessels to their normal size.

How is Otrivine Congestion Relief 0.1% Nasal Spray used?
This medicine should be sprayed once in each nostril one to three times per day, as needed.

Please read section 3 of the package leaflet for detailed information on how to take Otrivine Congestion Relief 0.1% Nasal Spray.

The medicine can be obtained without a prescription.

What benefits of Otrivine Congestion Relief 0.1% Nasal Spray have been shown in studies?
The formula for Otrivine Congestion Relief 0.1% Nasal Spray is similar to that for Otrivine Adult Nasal Drops, which have been used in the UK for more than 20 years. The benefits of Otrivine Congestion Relief 0.1% Nasal Spray are, therefore, taken as being the same as those of the reference medicine.
What are the possible side effects from Otrivine Congestion Relief 0.1% Nasal Spray?
Otrivine Congestion Relief 0.1% Nasal Spray can cause an allergic reaction and patients who suffer from difficulty breathing or swallowing, swelling of the face, lips, tongue or throat or severe itching of the skin with a red rash or raised bumps, should stop taking the nasal spray immediately and contact their doctor.

The most common side effects with Otrivine Congestion Relief 0.1% Nasal Spray (which may affect between 1 in 10 in every hundred people) are dryness or irritation of the nasal mucosa, nausea, headache and a local burning sensation in the area of the body where the spray is being used.

For the full list of all side effects reported with Otrivine Congestion Relief 0.1% Nasal Spray, see section 4 of the package leaflet. For the full list of restrictions, see the package leaflet.

Why was Otrivine Congestion Relief 0.1% Nasal Spray approved?
The MHRA decided that the benefits of Otrivine Congestion Relief 0.1% Nasal Spray are greater than its risks and recommended that it be approved for use.

What measures are being taken to ensure the safe and effective use of Otrivine Congestion Relief 0.1% Nasal Spray?
Safety information has been included in the Summary of Product Characteristics and the package leaflet for Otrivine Congestion Relief 0.1% Nasal Spray, including the appropriate precautions to be followed by healthcare professionals and patients.

Known side effects are continuously monitored. Furthermore new safety signals reported by patients/healthcare professionals will be monitored/reviewed continuously.

Other information about Otrivine Congestion Relief 0.1% Nasal Spray
The marketing authorisation for Otrivine Congestion Relief 0.1% Nasal Spray was granted on 10 July 2014.
For more information about treatment with Otrivine Congestion Relief 0.1% Nasal Spray, read the package leaflet or contact your doctor or pharmacist.

This summary was last updated in September 2014.

The full PAR for Otrivine Congestion Relief 0.1% Nasal Spray follows this summary.
OTRIVINE CONGESTION RELIEF 0.1% NASAL SPRAY

PL 00030/0461

SCIENTIFIC DISCUSSION

TABLE OF CONTENTS

Introduction .............................................. Page 5
Pharmaceutical assessment .......................... Page 6
Non-clinical assessment .............................. Page 8
Clinical assessment ................................ Page 9
Overall Conclusion and Benefit/Risk Assessment Page 10
INTRODUCTION

The Medicines and Healthcare products Regulatory Agency (MHRA) granted a Marketing Authorisation for the medicinal product Otrivine Congestion Relief 0.1% Nasal Spray to Novartis Consumer Health UK Limited on 10 July 2014. This General Sales List (GSL) medicine is used for the symptomatic relief of nasal congestion, perennial and allergic rhinitis (including hay fever) and sinusitis.

This application was submitted under Article 8(3) of Directive 2001/83/EC, as amended, as a line extension application. The reference medicinal product for this application is Otrivine Adult Nasal Drops (PL 00030/0115), which was first licensed to Ciba-Geigy plc under Marketing Authorisation number PL 00008/5023R. Following a change of ownership on 1 October 1997 the Marketing Authorisation for the reference product was transferred to Novartis Consumer Health UK Limited.

Xylometazoline is a sympathomimetic agent acting on alpha-adrenergic receptors in the nasal mucosa. When it is administered in the nose, it constricts the nasal blood vessels, thereby decongesting the mucosa of the nose and neighbouring regions of the pharynx. This decongests nasal passages and enables patients suffering from a blocked nose to breathe more easily. The effect of xylometazoline begins within a few minutes of administration and lasts for up to 10 hours.

No non-clinical or clinical studies were conducted, which is acceptable given that the application for this nasally-administered medicine makes reference to a medicinal product which has been licensed for over 10 years.

The MHRA has been assured that acceptable standards of Good Manufacturing Practice are in place for this product type at all sites responsible for the manufacture, assembly and batch release of the product.
PHARMACEUTICAL ASSESSMENT

ACTIVE SUBSTANCE: XYLOMETAZOLINE HYDROCHLORIDE

Chemical name: 2-[4-(1,1-Dimethylethyl)-2,6-dimethylbenzyl]-4,5-dihydro-1H-imidazole hydrochloride

Structure:

Molecular formula: \( \text{C}_{16}\text{H}_{24}\text{N}_2\text{HCl} \)
CAS registry number: 1218-35-5

Xylometazoline hydrochloride is a white or almost white, crystalline substance which is soluble in water, freely soluble in ethanol and practically insoluble in ether, chloroform and benzene.

All aspects of the manufacture and quality control of the active substance are covered by a European Directorate for the Quality of Medicines & HealthCare Certificate of Suitability.

MEDICINAL PRODUCT: OTRIVINE CONGESTION RELIEF 0.1% NASAL SPRAY

Description and composition
The nasal spray is an opalescent, white solution, with a menthol and eucalyptol (cineole) odour. Each metered-dose spray delivers 0.14 mg of xylometazoline hydrochloride and the excipients sodium dihydrogen phosphate dihydrate, disodium phosphate dodecahydrate, sodium chloride, disodium edetate, levomenthol, cineole, sorbitol, polyoxyl hydrogenated castor oil (macrogol glycerol hydroxystearate) and purified water.

All excipients comply with their European Pharmacopoeia monographs and are, therefore, acceptable.

None of the other excipients contain materials of animal or human origin.

Pharmaceutical development
The objective of the development programme was to formulate a globally acceptable, stable product that could be used as an alternative to Otrivine Adult Nasal Drops.

Manufacture
A satisfactory batch formula has been provided for the manufacture of the product, along with an appropriate account of the manufacturing process. The manufacturing process has been validated and has shown satisfactory results.
Control of medicinal product
The finished product specification proposed is acceptable. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided that comply with the release specification. Certificates of Analysis have been provided for any working standards used.

Container closure system
The nasal spray is stored in a high density polyethylene bottle with a metered dose pump (materials in contact with product: low density polyethylene, stainless steel, compound PE/butyl) polypropylene nozzle with cap. Each bottle contains 10 ml nasal spray.

Satisfactory specifications and certificates of analysis have been provided for all packaging components. All primary packaging complies with the current European regulations concerning materials in contact with foodstuffs.

Stability
Stability studies were performed, in accordance with current guidelines, on batches of finished product manufactured by the finished product manufacturer and packed in the packaging proposed for marketing. The results from these studies support a shelf life of 30 months when the nasal spray is stored in an unopened container and of 28 days once the bottle is first opened. These shelf lives apply when the storage precautions ‘Do not store above 25°C’ and ‘Store in the original package’ are adhered to.

Summary of Product Characteristics (SmPC), Patient Information Leaflet (PIL) and labelling
The SmPC, PIL and labelling are satisfactory from a pharmaceutical perspective.

The results of consultations with target patient groups (‘user testing’), in accordance with Article 59 of Council Directive 2001/83/EC, as amended, for the package leaflet for Otrivine Congestion Relief 0.1% Nasal Spray were provided. The results indicate that the package leaflet is well structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

Marketing Authorisation Application (MAA) form
The MAA form is satisfactory from a pharmaceutical perspective.

Quality Overall Summary
The quality overall summary is written by an appropriately qualified person and is a suitable summary of the pharmaceutical aspects of the dossier.

Conclusion
The grant of a Marketing Authorisation is recommended.
NON-CLINICAL ASSESSMENT

As the pharmacodynamic, pharmacokinetic and toxicological properties of xylometazoline hydrochloride are well-known, no non-clinical studies are required and none have been provided.

The applicant’s non-clinical expert report has been written by an appropriately qualified person and is satisfactory, providing an appropriate review of the product’s pharmacology and toxicology.

As Otrivine Congestion Relief 0.1% Nasal Spray is intended to be used as an alternative to Otrivine Adult Nasal Drops, no increase in environmental burden is expected. Thus, the non-submission of an environmental risk assessment is accepted.

There are no objections to the approval of this product from a non-clinical viewpoint.
CLINICAL ASSESSMENT

CLINICAL PHARMACOLOGY
Otrivine Congestion Relief 0.1% Nasal Spray is an aqueous solution. No bioequivalence studies are required for this type of product according to the guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1/Corr) and the applicant has submitted none.

EFFICACY
No new data on efficacy have been submitted and none are required for this type of application.

SAFETY
No new data on safety have been submitted and none are required for this type of application.

EXPERT REPORT
The clinical expert report has been written by an appropriately qualified physician and is a suitable summary of the clinical aspects of the dossier.

SUMMARY OF PRODUCT CHARACTERISTICS (SmPC)
This is consistent with the SmPC for Otrivine Adult Nasal Drops and is satisfactory.

PATIENT INFORMATION LEAFLET (PIL)
This is consistent with the PIL for Otrivine Adult Nasal Drops and is satisfactory.

LABELLING
This is satisfactory

MARKETING AUTHORISATION APPLICATION (MAA) FORM
The MAA form is satisfactory from a clinical perspective.

CONCLUSION
The grant of a marketing authorisation is recommended for this application.
OVERALL CONCLUSION AND BENEFIT/RISK ASSESSMENT

QUALITY
The important quality characteristics of Otrivine Congestion Relief 0.1% Nasal Spray are well defined and controlled. The specifications and batch analytical results indicate consistency from batch to batch. There are no outstanding quality issues that would have a negative impact on the benefit/risk balance.

NON-CLINICAL
No new non-clinical data were submitted and none are required for this type of application.

CLINICAL
No new clinical data were submitted and none are required for this type of application.

PRODUCT LITERATURE
The SmPC, PIL and labelling are satisfactory and consistent with those for Otrivine Adult Nasal Drops.

BENEFIT/RISK ASSESSMENT
The quality of the product is acceptable, and no new non-clinical or clinical safety concerns have been identified. Extensive clinical experience with xylometazoline hydrochloride is considered to have demonstrated the therapeutic value of the substance. The benefit/risk balance is therefore considered to be positive.
# STEPS TAKEN FOR ASSESSMENT

<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>The MHRA received the Marketing Authorisation Application on 5 April 2012</td>
</tr>
<tr>
<td>2</td>
<td>Following standard checks and communication with the applicant the MHRA considered the application valid on 14 June 2012.</td>
</tr>
<tr>
<td>3</td>
<td>Following assessment of the application the MHRA requested information relating to the dossier on 21 September 2012, 30 April 2013 and 17 October 2013</td>
</tr>
<tr>
<td>4</td>
<td>The applicant responded to the MHRA’s requests providing further information on the dossier on 20 December 2012, 30 April 2013, 13 May 2013 and 25 March 2014</td>
</tr>
<tr>
<td>5</td>
<td>The application was granted on 10 July 2014.</td>
</tr>
</tbody>
</table>
SUMMARY OF PRODUCT CHARACTERISTICS

In accordance with Directive 2010/84/EU, the SmPCs for products granted Marketing Authorisations at a national level are available on the MHRA website.
PATIENT INFORMATION LEAFLET

In accordance with Directive 2010/84/EU, the PILs for products granted Marketing Authorisations at a national level are available on the MHRA website.
LABELLING

Label:
Carton: